Publication
The 2025 Dutch tax classification of the Brazilian FIP
The Dutch tax classification system for non-Dutch entities will undergo significant changes as of 1 January 2025.
Canada | Publication | October 2023
Norton Rose Fulbright lawyers Kristin Wall, Randy Sutton, Veronique Barry, Christopher Guerreiro and Sarah Pennington contributed the Canada chapters to the Practical Law Life Sciences Global Guide on commercialization and regulation. The Guide is published in a Q&A format by Thomson Reuters, which is a leading global platform for trusted, up-to-date legal know how across all major practice areas.
Life Sciences Commercialisation in Canada: Overview
The Q&A Guide to life sciences commercialisation in Canada provides an overview of Canada’s life sciences sector, pricing and state funding, distribution and sale, importing, advertising, patents, trade marks, competition law, and product liability.
Life Sciences Regulation in Canada: Overview
The Q&A guide to life sciences regulation in Canada reviews the main legislation governing pharmaceuticals in Canada. The guide provides an overview of key practical issues, including clinical trials, manufacturing, marketing, abridged procedures, pharmacovigilance, data privacy, packaging and labelling, biological medicines, medical devices, health care IT, combination products, and natural health products.
Publication
The Dutch tax classification system for non-Dutch entities will undergo significant changes as of 1 January 2025.
Publication
As previously observed, conflicts occasionally arise between mortgagees and charterers where a mortgagee wishes to take prompt action to enforce its rights, but the charterer wishes such enforcement action to be deferred until the end of the charter.
Publication
For some time now, the European Commission (EC) and national competition authorities (NCAs) have been striving to catch so-called “killer acquisitions” under their merger control rules to thereby close a perceived enforcement gap.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023